ESSA Pharma Inc. (NASDAQ:EPIX – Get Free Report) (TSE:EPI) COO Peter Virsik sold 2,082 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.03, for a total transaction of $12,554.46. Following the sale, the chief operating officer now directly owns 9,164 shares of the company’s stock, valued at approximately $55,258.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
ESSA Pharma Trading Up 6.1 %
NASDAQ EPIX traded up $0.34 during trading on Tuesday, hitting $5.93. 979,381 shares of the company’s stock were exchanged, compared to its average volume of 93,386. The company has a market cap of $263.07 million, a PE ratio of -9.41 and a beta of 1.82. ESSA Pharma Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $11.67. The stock’s 50 day moving average price is $5.12 and its two-hundred day moving average price is $6.49.
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last issued its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.10. Analysts forecast that ESSA Pharma Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Separately, Oppenheimer reaffirmed an “outperform” rating and set a $17.00 price objective on shares of ESSA Pharma in a research report on Thursday, May 16th.
Get Our Latest Stock Report on ESSA Pharma
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
- Five stocks we like better than ESSA Pharma
- 3 Tickers Leading a Meme Stock Revival
- 3 Small Cap Stocks That Insiders Are Buying
- How to Evaluate a Stock Before Buying
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.